Radioimmunotherapy for Head and Neck Cancer
Author Information
Author(s): M. Gerretsen, A.H.G.J. Schrijvers, M. van Walsum, B.J.M. Braakhuis, J.J. Quak, C.J.L.M. Meijer, G.B. Snow, G.A.M.S. van Dongen
Primary Institution: Free University Hospital, Amsterdam, The Netherlands
Hypothesis
Can 131I-labelled monoclonal antibody E48 effectively eradicate human head and neck squamous cell carcinoma xenografts in nude mice?
Conclusion
The study found that 131I-labelled MAb E48 can significantly delay tumor growth and even lead to complete remission in some cases.
Supporting Evidence
- Two out of seven tumors treated with 800uCi showed complete remission without regrowth.
- Median tumor volume doubling time increased significantly in treated groups compared to controls.
- No antitumor effects were observed in control groups.
Takeaway
This study shows that a special medicine can help mice with a type of throat cancer get better by making their tumors shrink or disappear.
Methodology
Nude mice with head and neck cancer xenografts were treated with different doses of 131I-labelled MAb E48 and compared to control groups.
Limitations
The study was conducted in a mouse model, which may not fully represent human responses.
Participant Demographics
Female nude mice, 8-10 weeks old.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website